Osgood said the key elements of this strategy include:
-- Resolving the GEHC issues that have impacted BioArchive sales.
-- Ramping AXP disposable production and generating increased activity
among both existing and new customers.
-- Developing the modular BioArchive.
-- Creating awareness of our stem cell brand and associated products
outside the cord blood markets
-- Ensuring use of our AXP products in adult stem cell, animal studies
and human clinical trials.
-- Identifying new ways of generating value for our surgical wound
-- Successful disposition of our legacy ThermoLine offering.
-- Continuing to evolve our management team and adding new members to the
board of directors in the near future.
Guidance for Fiscal 2008
The Company expects sequential revenue improvement throughout fiscal 2008 with accelerated growth in the later half of the fiscal year. Management intends to provide more specific revenue guidance in its first quarter fiscal 2008 earnings report.
The Company will hold a conference call today, September 12, 2007, at
7:30 a.m., Pacific Daylight Time (10:30 a.m., Eastern Daylight Time) to
review financial results and key operating developments. Please dial in 10
minutes prior to the beginning of the call. The call can be accessed by
dialing 1-800-860-2442 within the U.S. or 412-858-4600 outside the U.S. and
referencing conference, "ThermoGenesis". The call will also be available
via the Internet at
http://www.thermogenesis.com/investor_relations/index.asp. A replay of the
conference call will be available approximately two hours aft
|SOURCE ThermoGenesis Corp.|
Copyright©2007 PR Newswire.
All rights reserved